erlotinib hydrochloride has been researched along with dabrafenib in 5 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (dabrafenib) | Trials (dabrafenib) | Recent Studies (post-2010) (dabrafenib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 825 | 107 | 808 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | dabrafenib (IC50) |
|---|---|---|---|
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 0.077 | |
| GTPase KRas | Homo sapiens (human) | 5.88 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.15 | |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.026 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0033 | |
| TGF-beta receptor type-1 | Homo sapiens (human) | 3.7 | |
| Receptor-interacting serine/threonine-protein kinase 3 | Homo sapiens (human) | 0.126 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yaqub, F | 1 |
| Azan, A; Bakker Schut, TC; Besse, B; Boutros, C; Caspers, PJ; Eggermont, AM; Kamsu Kom, N; Koljenović, S; Lanoy, E; Mateus, C; Mir, LM; Noordhoek Hegt, V; Paci, A; Planchard, D; Puppels, GJ; Robert, C; Routier, E; Roy, S; Seck, A; Texier, M; Tomasic, G | 1 |
| Brown, B; Molloy, MP; Neilson, KA; Semaan, C | 1 |
| Niederer, R; Samalia, P; Sims, J | 1 |
| Choi, YS; Jeon, MJ; Kim, TY; Kim, WB; Kim, WG; Kwon, H; Shong, YK; You, MH | 1 |
1 trial(s) available for erlotinib hydrochloride and dabrafenib
| Article | Year |
|---|---|
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.
Topics: Aged; Algorithms; Antineoplastic Agents; Area Under Curve; Biomarkers; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Male; Middle Aged; Oximes; Pilot Projects; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; ROC Curve; Sensitivity and Specificity; Skin; Spectrum Analysis, Raman; Sulfonamides; Vemurafenib | 2017 |
4 other study(ies) available for erlotinib hydrochloride and dabrafenib
| Article | Year |
|---|---|
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells.
Topics: Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Mutation; Naphthyridines; Oximes; Phenazines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Sulfonamides | 2018 |
Drug-induced ocular inflammation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Brimonidine Tartrate; Diphosphonates; ErbB Receptors; Erlotinib Hydrochloride; Etanercept; Female; Humans; Imidazoles; Immune Checkpoint Inhibitors; Male; Middle Aged; Nivolumab; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Scleritis; Uveitis, Anterior; Vemurafenib; Zoledronic Acid | 2020 |
Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2022 |